

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 38. (cancelled)

39. (previously presented) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 22.

40. (cancelled)

41. (previously presented) An isolated polynucleotide comprising a nucleic acid sequence of SEQ ID NO: 21.

42. (previously presented) An isolated polynucleotide comprising a complement of the nucleic acid sequence of SEQ ID NO: 21.

43. (previously presented) A vector comprising the polynucleotide of claim 39.

44. (previously presented) The vector of claim 43, further comprising a promoter operably-linked to said polynucleotide.

45. (previously presented) A cell comprising the vector of claim 44.

46. (previously presented) The cell of claim 45, wherein said cell is a prokaryotic or a eukaryotic cell.

47. (previously presented) A process of producing a polypeptide comprising the amino acid sequence of SEQ ID NO: 22, the process comprising:

(a) providing the cell of claim 46, and;

(b) culturing the cell under conditions sufficient to express the polypeptide comprising the amino acid sequence of SEQ ID NO: 22,

thereby producing the polypeptide comprising the amino acid sequence of SEQ ID NO:

22.

48. (previously presented) The process of producing the polypeptide of claim 47, further comprising:

(c) recovering the polypeptide comprising the amino acid sequence of SEQ ID NO: 22,

thereby producing the polypeptide comprising the amino acid sequence of SEQ ID NO:

22.

49. (previously presented) A pharmaceutical composition comprising the polynucleotide of claim 39 and a pharmaceutically-acceptable carrier.

50. (cancelled)

51. (previously presented) An isolated polynucleotide consisting of a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 22.